ALX Oncology Holdings (ALXO)
(Delayed Data from NSDQ)
$1.45 USD
+0.02 (1.40%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $1.47 +0.02 (1.38%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
ALX Oncology Holdings Inc. (ALXO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$9.33 | $25.00 | $3.00 | 552.45% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for ALX Oncology Holdings Inc. comes to $9.33. The forecasts range from a low of $3.00 to a high of $25.00. The average price target represents an increase of 552.45% from the last closing price of $1.43.
Analyst Price Targets (6 )
Broker Rating
ALX Oncology Holdings Inc. currently has an average brokerage recommendation (ABR) of 1.57 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.57 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, five are Strong Buy, representing 71.43% of all recommendations. A month ago, Strong Buy represented 71.43%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.57 | 1.57 | 1.57 | 1.57 | 1.57 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/11/2024 | UBS | Trung Huynh | Not Available | Strong Buy |
8/12/2024 | Cantor Fitzgerald & Co | Li Watsek | Strong Buy | Strong Buy |
7/31/2024 | LifeSci Capital | Sam Slutsky | Strong Buy | Hold |
7/31/2024 | Not Identified | Not Identified | Hold | Hold |
7/11/2024 | Piper Sandler | Christopher Raymond | Strong Buy | Strong Buy |
6/10/2024 | H.C. Wainwright & Co. | Swayampakula Ramakanth | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.57 |
ABR (Last week) | 1.57 |
# of Recs in ABR | 7 |
Average Target Price | $9.33 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 89 of 252 |
Current Quarter EPS Est: | -0.78 |
ALXO FAQs
ALX Oncology Holdings Inc. (ALXO) currently has an average brokerage recommendation (ABR) of 1.57 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 7 brokerage firms.
The average price target for ALX Oncology Holdings Inc. (ALXO) is $9.33. The current on short-term price targets is based on 6 reports.
The forecasts for ALX Oncology Holdings Inc. (ALXO) range from a low of $3 to a high of $25. The average price target represents a increase of $543.45 from the last closing price of $1.45.
The current UPSIDE for ALX Oncology Holdings Inc. (ALXO) is 543.45%
Based on short-term price targets offered by six analysts, the average price target for ALX Oncology Holdings Inc. comes to $9.33. The forecasts range from a low of $3.00 to a high of $25.00. The average price target represents an increase of 552.45% from the last closing price of $1.43.